Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab; and antibody collaboration with Regeneron Pharmaceuticals, Inc. to develop antibodies, such as Dupixent (dupilumab) as treatment for diseases driven by type 2 inflammation. manufacturing facility in Germany. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
What does it do?
Sanofi is a French pharmaceutical giant that makes medicines and vaccines used by hundreds of millions of people worldwide. Their biggest product is Dupixent, an injection that treats eczema, asthma, and other inflammatory conditions — think of it as a medicine that calms down an overactive immune system. They also make vaccines for diseases like polio, flu, and rabies. If you or your child has ever had a routine childhood vaccine in Europe or the US, there's a decent chance Sanofi made it.
Sanofi is one of the largest drugmakers in the world with a $106 billion market value, which means it moves markets and sets trends in the pharmaceutical industry. Dupixent has become one of the best-selling drugs on the planet and is still growing fast, making Sanofi a live case study in how a single blockbuster drug can transform a company. Investors are watching closely to see whether Sanofi can build on that success or becomes dangerously dependent on one product.
How does it make money?
Sanofi makes money by selling prescription medicines and vaccines to hospitals, pharmacies, and healthcare systems around the world. Their biggest money-maker is Dupixent, which brought in roughly $14 billion in sales in the most recent year and is still growing at double-digit rates. Beyond Dupixent, they earn revenue from rare disease treatments, cancer drugs, and a large vaccines division. Total revenue reached $43.6 billion last year, up from $41.1 billion the year before, and they kept $7.8 billion as net profit — a healthy margin for this industry.
Why do investors care?
The core growth story at Sanofi right now is Dupixent. The drug keeps getting approved for new conditions — it started with eczema and has since expanded to asthma, nasal polyps, and more — which means its potential patient pool keeps growing. Sanofi is also investing heavily in AI-assisted drug discovery through a partnership with Exscientia, betting that smarter technology can help them find the next Dupixent faster. For the thesis to work, Dupixent needs to keep growing, new drugs in the pipeline need to get approved, and Sanofi needs to avoid costly clinical trial failures.
Deep Dive
MemberA full investor briefing on Sanofi — history, leadership, risks, and outlook.